Teplizumab + Placebo

Phase 2/3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
65
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes Mellitus

Conditions

Type 1 Diabetes Mellitus

Trial Timeline

Oct 1, 2006 โ†’ Aug 1, 2011

About Teplizumab + Placebo

Teplizumab + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT00385697. Target conditions include Type 1 Diabetes Mellitus.

Hype Score Breakdown

Clinical
22
Activity
15
Company
10
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT00385697Phase 2/3Completed